Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Kim Kelly, RN, OCN

Advertisement

Articles by Kim Kelly, RN, OCN

Kim Kelly on Clinical Practice Guidelines for Mucositis

ByKim Kelly, RN, OCN
May 2nd 2012

Kim Kelly, from John Theurer Cancer Center, on the Updated MASCC/ISOO Clinical Practice Guidelines for Mucositis

Advertisement

Latest Updated Articles

  • Kim Kelly on Clinical Practice Guidelines for Mucositis
    Kim Kelly on Clinical Practice Guidelines for Mucositis

    May 2nd 2012



Advertisement
Advertisement

Trending on OncLive

1

FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL

2

Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML

3

Revisit Every OncLive On Air Episode From September 2026

4

UTRxMYCN M1-14 Nets FDA Dual Designations in Soft Tissue Sarcoma

5

Optune Pax Is Approved in Japan for Unresectable Locally Advanced Pancreatic Cancer

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us